|
|
|
|
|
|
|
26.05.26 - 22:31
|
Gilead Sciences Aktie nach Q1 2026 Zahlen: 180 oder 122 USD? Analysten-Kursziele und Ratings (Aktiencheck)
|
|
|
Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen Unternehmens Gilead Sciences Inc. (ISIN: US3755581036, WKN: 885823, Ticker-Symbol: GIS, NASDAQ-Symbol: GILD) nach Bekanntgabe der Q1 2026 Zahlen zu? 180,00 oder 122,00 USD? Wir haben Ihnen die aktuellen Kursziele und Ratings zur Gilead Sciences-Aktie auf einen Blick zusammengestellt. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
22.05.26 - 12:36
|
Gilead Sciences acquires Tubulis for $5bn (PBR)
|
|
|
First announced last month, the move aims to advance Gilead's oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a
The post Gilead Sciences acquires Tubulis for $5bn appeared first on Pharmaceutical Business review....
|
|
|
21.05.26 - 15:36
|
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio (Business Wire)
|
|
|
– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform –FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).
The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable the development of unique ADCs with superior biophysical properties, capable of achieving robust on-tumor payload exposure that can translate to long-lasting anti-tumor activity. The addition of Tubulis' lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, which has demonstrated promising activity in platinum-resistant ovarian cancer, and TUB-030,...
|
|
|
21.05.26 - 09:33
|
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease (Business Wire)
|
|
|
- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year -FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated.
The expanded agreement aims to improve access to life-saving diagnostic services and treatment for some of the world's most vulnerable communities, with a sharpened focus on high-burden countries in East Africa. Gilead is committed to improving global health by advancing innovative treatments and partnering with organizations such as WHO to broaden access to medicines and help eliminate diseases like VL.
"Ending visceral leishmaniasis is ...
|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.26 - 03:27
|
Gilead Prices $3 Billion of Senior Unsecured Notes (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions.
Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities.
Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The off...
|
|
|
|
|
14.05.26 - 13:06
|
Veeva Commercial Summit to Feature Biopharma′s AI Successes and the Path to Agentic Commercial (PR Newswire)
|
|
|
argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
